Design, synthesis and biological evaluation of [1,2,3]triazolo[4,5-d]pyrimidine derivatives possessing a hydrazone moiety as antiproliferative agents. 2016

Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
School of Pharmaceutical Science & Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou University, Zhengzhou, 450001, PR China.

A series of [1,2,3]triazolo[4,5-d]pyrimidine derivatives bearing a hydrazone moiety were designed, synthesized and evaluated for their antiproliferative activity against several cancer cell lines of different origins by MTT assay. Most of the synthesized compounds demonstrated moderate to good activity against the cancer cell lines selected. Especially, compound 43 showed the most potent antiproliferative activity as well as good selectivity between cancer and normal cells (IC50 values of 0.85 μM against MGC-803 and 56.17 μM against GES-1). In addition, compound 43 evidently inhibited the colony formation of MGC-803 cells at 0.8 μM. Further mechanism studies revealed that compound 43 could induce apoptosis of MGC-803 cells probably through the mitochondrial pathway accompanied with decrease of the mitochondrial membrane potential (MMP), activations of caspase-9/3, up-regulation of the expression of Bax, Bak and PUMA, as well as down-regulation of that of Bcl-2 and Mcl-1.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006835 Hydrazones Compounds of the general formula R:N.NR2, as resulting from the action of hydrazines with aldehydes or ketones. (Grant & Hackh's Chemical Dictionary, 5th ed) Hydrazone
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
October 2017, European journal of medicinal chemistry,
Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
February 2018, European journal of medicinal chemistry,
Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
December 2020, Bioorganic chemistry,
Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
February 2020, European journal of medicinal chemistry,
Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
August 2020, Bioorganic & medicinal chemistry letters,
Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
April 2017, ACS medicinal chemistry letters,
Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
August 2017, MedChemComm,
Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
October 2019, Bioorganic chemistry,
Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
June 2023, Chemistry & biodiversity,
Zhong-Hua Li, and Dong-Xiao Yang, and Peng-Fei Geng, and Ji Zhang, and Hao-Ming Wei, and Biao Hu, and Qian Guo, and Xin-Hui Zhang, and Wen-Ge Guo, and Bing Zhao, and Bin Yu, and Li-Ying Ma, and Hong-Min Liu
May 2024, Chemistry & biodiversity,
Copied contents to your clipboard!